Clinical Trials
151
54 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1964
Active, not recruiting
9
6.0%
Completed
59
39.1%
Not yet recruiting
45
29.8%
Recruiting
28
18.5%
Terminated
8
5.3%
Withdrawn
2
1.3%
No approval data available
- New South Wales has completed construction of a $96 million RNA Research and Manufacturing Facility at Macquarie University, creating Australia's only comprehensive RNA therapeutics production site under one roof. - The facility addresses critical gaps exposed during COVID-19 by establishing domestic RNA manufacturing capability for vaccines and treatments, with the NSW Government committing an additional $119 million over 10 years for R&D projects. - University of Sydney spinout Vaxosome has secured NSW RNA Pipeline Grant funding to develop a multiplexed mRNA vaccine platform targeting tuberculosis, which kills over 1.3 million people globally each year. - The developments position NSW as a leader in RNA medicine, spanning applications from next-generation vaccines to cancer treatments and rare genetic disease therapies.
- The RESTORE trial demonstrates that cognitive functional therapy (CFT) produces clinically important reductions in chronic low back pain and activity limitations that persist for three years. - CFT, delivered through seven sessions by specially trained physiotherapists, significantly outperformed usual care in reducing both pain intensity and physical activity limitations. - This represents the first large, high-quality study investigating long-term CFT outcomes, offering potential to markedly reduce the global burden of chronic back pain. - The biopsychosocial approach addresses physical, psychological and social factors while empowering patients with self-management skills and confidence to move.
- Tofersen, developed by Biogen, has demonstrated significant efficacy in slowing the progression of MND in patients with the SOD1 genetic mutation, offering a breakthrough in treatment for this previously untreatable condition. - Despite being available through Biogen's Extended Access Program at no cost, some patients face barriers to access as the NHS struggles with administration costs and capacity for the monthly lumbar puncture procedure. - Clinical trials, including the ATLAS study, show particularly promising results when treatment begins before symptom onset, with some patients remaining symptom-free despite elevated neurofilament levels indicating disease activation.
- A Phase II clinical trial is underway at Macquarie University, combining doxycycline and ambroxol to combat Dementia with Lewy Bodies (DLB). - Doxycycline prevents alpha-synuclein clumping, while ambroxol boosts an enzyme that clears these protein clusters, addressing key pathological features of DLB. - Early diagnosis of DLB is crucial to avoid misdiagnosis and ensure appropriate treatment, as symptoms overlap with other conditions like Parkinson's and Alzheimer's. - The trial involves a six-month regimen of the dual-drug therapy, aiming to slow or halt the progression of DLB, which affects approximately 20% of Australian dementia patients.
